Key result
Sintilimab plus P-Gemox fails to halt disease progression in a case of cardiac NK/T-cell lymphoma.
Why the study?
Extranodal NK/T-cell lymphoma invading the heart is extremely rare and lacks an effective therapeutic strategy due to limited reported cases.
Case Report (n=1)
No
This case report highlights a rare presentation of extranodal NK/T-cell lymphoma invading the heart, treated with Sintilimab and P-Gemox, with a survival of 2 months.
Poor prognosis in cardiac NK/T-cell lymphoma; leaves open optimal therapy for this rare entity.
Extranodal NK/T-cell lymphoma (ENKTL) is a rare but aggressive subtype of non-Hodgkin lymphoma, which is derived from NK cells or T cells. There are very few cases of ENKTL invading the heart. Only 12 cases of ENKTL invading the heart have been reported in the English literature. Due to the rarity of this lymphoma, an effective therapeutic strategy has not been defined. Here, we present a case of a 51-year-old Chinese male with extranodal NK/T-cell lymphoma invading the heart and review the literature. The patient received a chemotherapy regimen of PD1 monoclonal antibody (Sintilimab) in combination with first-line P-Gemox. The patient survived for 2 months after diagnosis.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2022) conducted a case report in Extranodal natural killer/T-cell lymphoma (ENKTL) invading the heart (n=1). Sintilimab in combination with P-Gemox was evaluated on Survival. In a 51-year-old man with extranodal NK/T-cell lymphoma invading the heart, treatment with sintilimab combined with P-Gemox did not halt disease progression, and the patient died 2 months after diagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: